From the Department of Ophthalmology & Visual Neurosciences, University of Minnesota Medical School (R.M., J.M.K., E.H.R., P.H.T.); College of Biological Sciences, University of Minnesota, - Twin Cities (A.V.); and Vitreo Retinal Surgery, P.L.L.C., (G.S.S., P.J.B., E.H.R., P.H.T.), Minneapolis, Minnesota, USA.
From the Department of Ophthalmology & Visual Neurosciences, University of Minnesota Medical School (R.M., J.M.K., E.H.R., P.H.T.); College of Biological Sciences, University of Minnesota, - Twin Cities (A.V.); and Vitreo Retinal Surgery, P.L.L.C., (G.S.S., P.J.B., E.H.R., P.H.T.), Minneapolis, Minnesota, USA.
Am J Ophthalmol. 2022 May;237:49-57. doi: 10.1016/j.ajo.2021.11.017. Epub 2021 Nov 19.
To evaluate the effect of 1 full year of the coronavirus disease 2019 (COVID-19) pandemic on clinical presentation of acute, primary rhegmatogenous retinal detachment (RRD).
Single-center, retrospective observational cohort study.
Patients were divided into 2 cohorts: consecutive patients treated for primary RRD during the COVID-19 pandemic (March 9, 2020, to March 7, 2021; pandemic cohort) and patients treated during the corresponding time in previous year (March 11, 2019, to March 8, 2020; control cohort).
Proportion of patients presenting with macula-involving (mac-off) or macula-sparring (mac-on) RRD.
A total of 952 patients in the pandemic cohort and 872 patients in the control cohort were included. Demographic factors were similar. Compared with the control cohort, a significantly greater number of pandemic cohort patients presented with mac-off RRDs ([60.92%] pandemic, [48.17%] control, P = .0001) and primary proliferative vitreoretinopathy ([15.53%] pandemic, [6.9%] control, P = .0001). Pandemic cohort patients (10.81%) had significantly higher rates of lost to follow-up compared with the control cohort (4.43%; P = .0001). Patients new to our clinic demonstrated a significant increase in mac-off RRDs in the pandemic cohort (65.35%) compared with the control cohort (50.40%; P = .0001). Pandemic cohort patients showed worse median final best-corrected visual acuity (0.30 logarithm of the minimum angle of resolution) compared with the control cohort (0.18 logarithm of the minimum angle of resolution; P = .0001).
Patients with primary RRD during the first year of the COVID-19 pandemic were more likely to have mac-off disease, present with primary proliferative vitreoretinopathy, be lost to follow-up, and have worse final best-corrected visual acuity outcomes.
评估 2019 年冠状病毒病（COVID-19）大流行对急性原发性孔源性视网膜脱离（RRD）临床表现的影响。
单中心回顾性观察队列研究。
患者分为 2 个队列：COVID-19 大流行期间（2020 年 3 月 9 日至 2021 年 3 月 7 日）连续接受原发性 RRD 治疗的患者（大流行队列）和同年（2019 年 3 月 11 日至 2020 年 3 月 8 日）接受治疗的患者（对照组）。
患黄斑受累（mac-off）或黄斑未受累（mac-on）RRD 的患者比例。
大流行队列纳入 952 例患者，对照组纳入 872 例患者。两组患者的人口统计学因素相似。与对照组相比，大流行队列中黄斑受累 RRD 患者（[60.92%]大流行，[48.17%]对照组，P=0.0001）和原发性增生性玻璃体视网膜病变（[15.53%]大流行，[6.9%]对照组，P=0.0001）的数量明显增加。与对照组（4.43%）相比，大流行队列患者的失访率（10.81%）显著升高（P=0.0001）。新入本诊所的患者在大流行队列中（65.35%）黄斑脱离 RRD 明显高于对照组（50.40%）（P=0.0001）。与对照组相比（0.18 对数最小角分辨率），大流行队列患者的最终最佳矫正视力中位数（0.30 对数最小角分辨率）更差（P=0.0001）。
COVID-19 大流行第一年接受原发性 RRD 治疗的患者更有可能患黄斑脱离疾病，出现原发性增生性玻璃体视网膜病变，失访，并出现更差的最终最佳矫正视力结果。
